

## Changes in the company's administrative structure at the level of executive management

## الإفصاح عن التغييرات في الهيكل الإداري للشركة على مستوى الادارة التنفيذية

Gulf Pharmaceutical Industries (Julphar) announces the appointment of the company's Financial Officer, Mr. Lauterbach, to the position of Chief Corporate Development and Strategy Officer of the Julphar Group

تعلن شركة الخليج للصناعات الدوائية (جلفار) عن تعيين السيد/ يورجن لوترباخ في منصب رئيس التطوير المؤسسي والاستراتيجي لمجموعة جلفار. والذي قد شغل من قبل منصب الرئيس المالي للشركة.

In this new responsibility Juergen Lauterbach been entrusted with driving the company's future strategic growth initiatives, investment projects and merger and acquisition activities. He will also lead the development of the group's strategy and the implementation of the company's new product pipeline initiatives.

وقد أسند إليه عدة مهام من ضمنها مبادرات النمو الإستراتيجي المستقبلي، ومشاريع الاستثمار والأنشطة المتعلقة بالإندماج والإستحواذ الخاصة بشركة جلفار. كما سيعمل على قيادة عملية التطوير الإستراتيجي للمجموعة وتنفيذ مبادرات الشركة الجديدة.

company also announces the The appointment of Mr. Ignacio Anglada as the company's new Chief Financial Officer, effective May 09, 2022. (Disclosure attached).

كما تعلن الشركة تعيين السيد/ إيجناسيو أنجلادا، بمنصب الرئيس المالى الجديد للشركة اعتبارا من تاريخ 09 مايو 2022م. (مرفق الإفصاح الخاص به).

The Name of the Authorized Signatory	Rayan Omer
Designation	Board Secretary
Signature and Date	17/05/2022
Company's Seal	The state of the s
	(Julphar)

## Changes in the company's administrative structure at the level of executive management

Date	17.05.2022
Name of the Listed Company:	Gulf Pharmaceutical Industries JULPHAR
The name of the person appointed:	Mr. IGNACIO ANGLADA
Position:	Chief Finance Officer (CFO)
Date of the board decision that approved the appointment:	08.04.2022
Starting date of appointment:	09.05.2022
A brief summary of the CV for the designated	Ignacio brings a wealth of experience of more than 20-year finance career mainly in Pharma, which includes senior leadership roles in Novartis for more than 16 years, both in commercial and technical operations.  During his career, mainly developed in Novartis, Ignacio has worked in finance roles of increasing responsibility, including strategy, CFO, commercial and technical operations finance roles, in local and global positions, across different countries and regions.  Ignacio holds an MBA from ESADE Business School, and Degree in Finance, Business and Administration from Barcelona University.  Finance Excellence Program — HARVARD BUSINESS SCHOOL  Finance Leadership Program — NOVARTIS ACADEMY

The Name of the Authorized Signatory	Rayan Omer
Designation	Company Secretary
Signature and Date	17.05.2022
Company's Seal	Stormacoutled Indian